
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Performing Endoscopy Safely in Pregnant Patients: Best Practices for the Gastroenterology Team  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Performing Endoscopy Safely in Pregnant Patients: Best Practices for the Gastroenterology Team  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: American Journal of Gastroenterology, Jan 2026  </li>
<li style="margin-left: 0px;">Topic: Endoscopic care during pregnancy  </li>
</ul>
<details><summary><strong>1. Introduction &amp; Epidemiology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">~0.4% of GI endoscopies occur during gestation.  </li>
<li style="margin-left: 0px;">Goal: safe, effective GI endoscopy while minimizing maternal‑fetal risks.  </li>
<li style="margin-left: 0px;">Review synthesizes guidelines, literature, author experience → best‑practice table (Table 1).  </li>
</ul>
</div></details>
<details><summary><strong>2. Maternal &amp; Fetal Risks Overview  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Absolute risk quantification limited; data sparse.  </li>
<li style="margin-left: 0px;">Large cohort study: ↑ preterm birth, ↓ fetal growth; no ↑ stillbirth or congenital malformations.  </li>
<li style="margin-left: 0px;">Residual confounding – disease vs procedure unclear.  </li>
</ul>
<details><summary><strong>2.1 Specific Maternal Risks (Table 2)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Oversedation → hypotension, hypoventilation, hypoxia.  </li>
<li style="margin-left: 0px;">Aspiration risk ↑ due to reduced LES tone &amp; increased intra‑abdominal pressure.  </li>
<li style="margin-left: 0px;">Bronchospasm, hypoxemia, hemodynamic instability.  </li>
</ul>
</div></details>
<details><summary><strong>2.2 Specific Fetal Risks (Table 2)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Hypoxia/hypoperfusion → fetal acidosis.  </li>
<li style="margin-left: 0px;">Radiation exposure: &lt;50 mGy typical ERCP; threshold for concern ≈100 mGy.  </li>
<li style="margin-left: 0px;">Supine/IVC compression → maternal hypotension → placental hypoperfusion.  </li>
<li style="margin-left: 0px;">Teratogenic meds, contrast‑induced hypothyroidism, amniotic fluid conduction of electrocautery current.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Preprocedural Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Multidisciplinary triage mandatory (GI, obstetrics/MFM, anesthesia).  </li>
</ul>
<details><summary><strong>3.1 Indication &amp; Timing  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Elective cases → postpone until postpartum.  </li>
<li style="margin-left: 0px;">Urgent/ emergent indications (e.g., cholangitis, GI bleed) → proceed after risk‑benefit analysis.  </li>
<li style="margin-left: 0px;">Align decisions with patient values/preferences.  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Contraindications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Imminent delivery, ruptured membranes.  </li>
<li style="margin-left: 0px;">Obstetric complications: placental abruption, eclampsia.  </li>
</ul>
</div></details>
<details><summary><strong>3.3 Informed Consent Modifications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Discuss disease‑related vs procedure‑related risks (both often “difficult to quantify”).  </li>
<li style="margin-left: 0px;">Emphasize trust‑building, transparent risk communication.  </li>
</ul>
</div></details>
<details><summary><strong>3.4 Preoperative Consultations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Obstetrician: assess maternal/fetal status; plan fetal monitoring pre/post.  </li>
<li style="margin-left: 0px;">Anesthesiologist: airway edema, ↓ functional residual capacity, cephalad stomach displacement → adjust ventilation, positioning, drug choice.  </li>
</ul>
<details><summary><strong>3.4.1 Sedative &amp; Analgesic Safety (Table 3)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Short‑acting agents in low doses generally safe.  </li>
<li style="margin-left: 0px;">Avoid high‑dose benzodiazepines, propofol without obstetric input.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.5 Periprocedural Medications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Bowel prep: polyethylene glycol first choice.  </li>
<li style="margin-left: 0px;">Antibiotics: penicillin, cephalexin, metronidazole, ciprofloxacin acceptable.  </li>
<li style="margin-left: 0px;">NSAIDs: may use in 1st trimester (↑ miscarriage risk) → avoid after 20 wk (risk of ductus arteriosus closure, oligohydramnios).  </li>
<li style="margin-left: 0px;">Indomethacin (rectal) – case‑by‑case for ERCP; consider prophylactic pancreatic duct stent &amp; hydration.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Procedural Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Experienced endoscopist + dedicated team essential.  </li>
</ul>
<details><summary><strong>4.1 General Technical Goals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Minimize procedure time, cautery use, fluoroscopy duration.  </li>
<li style="margin-left: 0px;">For ERCP: prefer standard cannulation with brief fluoroscopic pulses; avoid experimental “fluoro‑free” techniques until validated.  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Patient Positioning  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Left lateral decubitus or left pelvic tilt preferred for all GI endoscopies after 20 wk to prevent IVC/aortic compression.  </li>
<li style="margin-left: 0px;">Colonoscopy: underwater insertion, avoid abdominal pressure; if needed, apply away from uterus.  </li>
</ul>
</div></details>
<details><summary><strong>4.3 Electrosurgery Safety  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Use bipolar cautery over monopolar when possible.  </li>
<li style="margin-left: 0px;">Grounding pad placement: right thorax/right shoulder/right arm → keep uterus out of current path.  </li>
<li style="margin-left: 0px;">Limit voltage &amp; duration of electrocautery (amniotic fluid conducts electricity).  </li>
</ul>
</div></details>
<details><summary><strong>4.4 Intra‑operative Injections  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Methylene blue &amp; epinephrine contraindicated (teratogenicity) – may consider epinephrine if benefit outweighs risk.  </li>
<li style="margin-left: 0px;">No evidence to avoid contrast in ERCP despite theoretical thyroid risk.  </li>
</ul>
</div></details>
<details><summary><strong>4.5 Radiation Management (ERCP/Fluoroscopy)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Typical fetal dose: 0.001–1.8 mGy (mean fluoroscopy time 0.14 min).  </li>
<li style="margin-left: 0px;">Threshold for concern ≈100 mGy; modern ERCP usually &lt;10–15 mGy.  </li>
<li style="margin-left: 0px;">Provide total radiation dose in post‑procedure report.  </li>
</ul>
<details><summary><strong>4.5.1 Fluoroscopy Best Practices (Table 4)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Discontinue routine lead shielding – may increase scatter &amp; degrade image quality.  </li>
<li style="margin-left: 0px;">Use pulsed (“short taps”) fluoroscopy, low‑dose settings, tight collimation.  </li>
<li style="margin-left: 0px;">Keep image intensifier close; avoid magnification unless essential.  </li>
<li style="margin-left: 0px;">Prefer wire‑guided cannulation; confirm biliary access by bile aspiration.  </li>
</ul>
</div></details>
</div></details>
</div></details>
<details><summary><strong>5. Postprocedural Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Obstetrician present for fetal monitoring &amp; interventions.  </li>
</ul>
<details><summary><strong>5.1 Monitoring Timeline  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">&lt;24 wk: Doppler fetal heart rate check post‑procedure.  </li>
<li style="margin-left: 0px;">≥24 wk: electronic fetal heart and uterine contraction monitoring after procedure.  </li>
</ul>
</div></details>
<details><summary><strong>5.2 Complication Surveillance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Early detection of maternal hypoxia, bleeding, perforation, pancreatitis (ERCP ↑ risk OR ≈ 2.8).  </li>
<li style="margin-left: 0px;">Prompt obstetric evaluation if premature labor signs or fetal distress arise.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Summary &amp; Clinical Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopy in pregnancy feasible with structured multidisciplinary protocol.  </li>
<li style="margin-left: 0px;">Core principle: <strong>risk‑benefit balance</strong> → prioritize maternal indication, fetal safety.  </li>
</ul>
<details><summary><strong>6.1 Key Take‑aways (Table 1 synthesis)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Provide non‑endoscopic alternatives when available.  </li>
<li style="margin-left: 0px;">Classify cases: elective → postpone; urgent/emergent → proceed after consent.  </li>
<li style="margin-left: 0px;">Involve obstetrics &amp; anesthesia early; ensure fetal monitoring capability.  </li>
<li style="margin-left: 0px;">Use experienced endoscopy team; adopt left lateral/pelvic tilt positioning.  </li>
<li style="margin-left: 0px;">Minimize procedure time, cautery, and fluoroscopy exposure.  </li>
</ul>
</div></details>
<details><summary><strong>6.2 Post‑procedure Follow‑up Algorithm  </strong></summary><div style="padding-left: 20px;">
<p>1. Immediate maternal vitals check → address hypoxia, hypotension.</p>
<p>2. Fetal heart rate assessment per gestational age (Doppler &lt;24 wk; electronic &gt;24 wk).</p>
<p>3. Observe for procedure‑specific complications: bleeding, perforation, pancreatitis.</p>
<p>4. Schedule obstetric follow‑up within 24–48 h for any concerning signs.</p>
</div></details>
</div></details>
<details><summary><strong>7. Medication Safety Profiles in Pregnancy (Expanded Table 3)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Categories based on US‑FDA/AU‑TGA and TERIS risk levels; data quality noted.  </li>
</ul>
<details><summary><strong>7.1 Prokinetics &amp; Antiemetics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Metoclopramide: NA/A, <strong>None</strong>, fair–good evidence → safe.  </li>
<li style="margin-left: 0px;">Erythromycin: B/A, <strong>None to minimal</strong>, fair–good → acceptable for gastric motility.  </li>
</ul>
</div></details>
<details><summary><strong>7.2 Antibiotics (common GI indications)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Drug</th>
<th>FDA/TGA</th>
<th>TERIS</th>
<th>Teratogenic risk</th>
<th>Data quality</th>
</tr></thead>
<tbody>
<tr>
<td>Penicillin</td>
<td>B/A</td>
<td>None</td>
<td><strong>None</strong></td>
<td>Good–excellent</td>
</tr>
<tr>
<td>Cephalexin</td>
<td>B/A</td>
<td>Unlikely</td>
<td><strong>Low</strong></td>
<td>Limited–fair</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>C/B3</td>
<td>Unlikely</td>
<td><strong>Low‑moderate</strong></td>
<td>Limited</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>B/B2</td>
<td>None to minimal</td>
<td><strong>Low</strong></td>
<td>Limited–fair</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>NA/B1</td>
<td>None to minimal</td>
<td><strong>Low</strong></td>
<td>Fair</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>C/B2</td>
<td>Undetermined</td>
<td><strong>Unclear</strong></td>
<td>Very limited</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>7.3 Acid‑Suppressive Therapy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pantoprazole (B/B3) – unlikely fetal risk, limited data.  </li>
<li style="margin-left: 0px;">Omeprazole (C/B3) – unlikely, fair–good evidence.  </li>
<li style="margin-left: 0px;">Famotidine (B/B1) – unlikely, limited‑fair data.  </li>
</ul>
</div></details>
<details><summary><strong>7.4 Bowel Preparations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Polyethylene glycol (C) – <strong>Undetermined</strong>, very limited data → preferred due to safety profile.  </li>
<li style="margin-left: 0px;">Sodium phosphate (C) – <strong>Undetermined</strong>, none; caution for fluid shifts/electrolyte imbalance.  </li>
</ul>
</div></details>
<details><summary><strong>7.5 NSAIDs &amp; COX‑2 Inhibitors  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Indomethacin (C/C) – unlikely teratogenicity, limited data; consider only when pancreatitis prophylaxis needed, monitor gestational age (&lt;20 wk).  </li>
</ul>
</div></details>
<details><summary><strong>7.6 Sedatives &amp; Analgesics for Moderate Sedation  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Drug</th>
<th>FDA/TGA</th>
<th>TERIS</th>
<th>Teratogenic risk</th>
<th>Data</th>
</tr></thead>
<tbody>
<tr>
<td>Fentanyl</td>
<td>C/C</td>
<td>Undetermined</td>
<td><strong>Unclear</strong></td>
<td>Limited</td>
</tr>
<tr>
<td>Midazolam</td>
<td>D/C</td>
<td>Undetermined</td>
<td><strong>Very limited</strong></td>
<td>Very limited</td>
</tr>
<tr>
<td>Ketamine</td>
<td>C/B3</td>
<td>Undetermined</td>
<td><strong>Very limited</strong></td>
<td>Very limited</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>7.7 Intraprocedural Injection Agents  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Methylene blue: C – intra‑amniotic moderate–high risk; systemic/topical data very limited → avoid.  </li>
<li style="margin-left: 0px;">Epinephrine: C – unlikely fetal effect, fair evidence → use only if hemostasis benefit outweighs risk.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Radiation Safety &amp; Fluoroscopy Optimization (Table 4 Details)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 General Principles  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Aim for <strong>≤10 mGy</strong> fetal dose; document exact exposure.  </li>
<li style="margin-left: 0px;">Discontinue routine abdominal lead shielding – may increase scatter and degrade image quality.  </li>
</ul>
</div></details>
<details><summary><strong>8.2 Technical Settings Checklist  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Pulsed fluoroscopy</strong> (“short taps”) → lower cumulative dose.  </li>
<li style="margin-left: 0px;"><strong>Low‑dose rate</strong> mode whenever available.  </li>
<li style="margin-left: 0px;"><strong>Tight collimation</strong> to region of interest; avoid unnecessary field size.  </li>
<li style="margin-left: 0px;"><strong>Image intensifier proximity</strong> – keep as close as possible to patient.  </li>
<li style="margin-left: 0px;"><strong>Manual exposure control</strong>: use 2–4 mA current, 75–80 kV voltage for dose reduction.  </li>
</ul>
</div></details>
<details><summary><strong>8.3 Image Acquisition Strategies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Utilize “last image hold” or digital storage; limit hard‑shot spot images to essential documentation.  </li>
<li style="margin-left: 0px;">Avoid boost/magnification unless clinically indispensable.  </li>
</ul>
</div></details>
<details><summary><strong>8.4 Procedural Technique Adjustments  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prefer <strong>wire‑guided biliary cannulation</strong> over contrast injection.  </li>
<li style="margin-left: 0px;">Confirm ductal access by bile aspiration or direct visualization rather than repeated fluoroscopic shots.  </li>
<li style="margin-left: 0px;">Consider <strong>staged ERCP</strong>: temporary stent placement now, definitive therapy postpartum if procedure predicted to be prolonged/complex.  </li>
</ul>
</div></details>
<details><summary><strong>8.5 Alternative Imaging Pathways  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform <strong>endoscopic ultrasound (EUS)</strong> first when feasible; can clarify stone burden/anatomy and potentially obviate need for fluoroscopy‑based ERCP.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Positioning Specifics by Trimester &amp; Procedure Type  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Trimester 1</strong>: Supine acceptable for brief ERCP to optimize cholangiogram, but still monitor maternal hemodynamics.  </li>
<li style="margin-left: 0px;"><strong>Trimester 2</strong>: Left pelvic tilt recommended; avoid full supine to reduce IVC compression.  </li>
<li style="margin-left: 0px;"><strong>&gt;20 wk (Trimester 3)</strong>: Strict left lateral decubitus or left pelvic tilt for all endoscopies; supine contraindicated due to aortic/IVC compression risk.  </li>
</ul>
<details><summary><strong>9.1 Colonoscopy Adjustments  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Underwater insertion technique reduces need for abdominal pressure.  </li>
<li style="margin-left: 0px;">If external pressure required, apply away from uterus.  </li>
</ul>
</div></details>
<details><summary><strong>9.2 ERCP Specifics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Position patient with left lateral tilt; ensure fluoroscopic C‑arm angled to minimize scatter toward fetus.  </li>
<li style="margin-left: 0px;">Use bipolar cautery if electrosurgical hemostasis needed; place grounding pad on right thorax/shoulder/arm.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Post‑procedure Monitoring Protocols (Expanded)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>10.1 Immediate Maternal Assessment  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Vital signs, oxygen saturation, airway patency.  </li>
<li style="margin-left: 0px;">Assess for aspiration, bronchospasm, bleeding.  </li>
</ul>
</div></details>
<details><summary><strong>10.2 Fetal Surveillance Timeline  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Gestational Age</th>
<th>Monitoring Modality</th>
<th>Timing</th>
</tr></thead>
<tbody>
<tr>
<td>&lt;24 wk</td>
<td>Doppler fetal heart rate</td>
<td>Within 30 min post‑procedure</td>
</tr>
<tr>
<td>≥24 wk</td>
<td>Continuous electronic fetal monitoring + uterine activity</td>
<td>Initiate within 15 min, continue ≥30 min</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>10.3 Complication Management Pathway  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Hypoxia</strong> → maternal oxygen supplementation, consider emergent obstetric evaluation.  </li>
<li style="margin-left: 0px;"><strong>Bleeding</strong> → endoscopic hemostasis (bipolar cautery/hemoclips) → monitor hemoglobin &amp; fetal status.  </li>
<li style="margin-left: 0px;"><strong>Pancreatitis post‑ERCP</strong> → aggressive IV hydration, analgesia (avoid NSAIDs after 20 wk), consider prophylactic pancreatic duct stent intra‑procedurally.  </li>
</ul>
</div></details>
<details><summary><strong>10.4 Discharge Criteria  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Stable maternal vitals ≥2 h, no ongoing bleeding or pain.  </li>
<li style="margin-left: 0px;">Fetal heart rate reassuring for at least 30 min post‑monitoring.  </li>
<li style="margin-left: 0px;">Clear instructions for emergency contact if uterine contractions or vaginal bleeding occur.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11. Supplementary &amp; Reference Resources  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Full tables (risk matrices, medication lists) available at http://links.lww.com/AJG/D694.  </li>
</ul>
<details><summary><strong>11.1 Key Guideline Sources  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">ASGE Standard of Practice Committee (2012) – endoscopy in pregnant/lactating women.  </li>
<li style="margin-left: 0px;">AAPM Position Statement (2019) – fetal shielding recommendations.  </li>
<li style="margin-left: 0px;">US FDA &amp; AU‑TGA drug classification databases – teratogenicity categories.  </li>
</ul>
</div></details>
<details><summary><strong>11.2 Core Evidence Cited  </strong></summary><div style="padding-left: 20px;">
<p>1. Ludvigsson JF et al., <em>Gastroenterology</em> 2017 – nationwide cohort, maternal–fetal outcomes post‑endoscopy.</p>
<p>2. Samara ET et al., <em>Gastrointest Endosc</em> 2009 – radiation dose assessment in therapeutic ERCP during pregnancy.</p>
<p>3. Inamdar S et al., <em>Clin Gastroenterol Hepatol</em> 2016 – increased pancreatitis risk post‑ERCP in pregnant cohort (adjusted OR 2.8).</p>
<p>4. Smith I et al., <em>World J Gastrointest Endosc</em> 2013 – mean fluoroscopy time 0.14 min, fetal dose 0.001–1.8 mGy.</p>
<p>5. Laudanno O et al., <em>Endosc Int Open</em> 2020 – long‑term follow‑up of children exposed to ERCP radiation (no developmental delays).</p>
</div></details>
<details><summary><strong>11.3 Additional Reading for Anesthetic Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Obiyo LT et al., <em>Curr Opin Anaesthesiol</em> 2024 – maternal–fetal anesthesia safety checklist.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>12. Conflict of Interest &amp; Funding Disclosure  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No financial support reported.  </li>
<li style="margin-left: 0px;">All authors declare no competing interests relevant to the content.  </li>
</ul>
</div></details>
<details><summary><strong>13. Implementation Checklist for Gastroenterology Units  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Team Formation</strong> – GI, obstetrics/MFM, anesthesiology; assign lead coordinator.</p>
<p>2. <strong>Pre‑procedure Protocol</strong> – consent script, medication safety chart, fetal monitoring plan.</p>
<p>3. <strong>Intra‑procedure SOP</strong> – positioning diagram (Figure 2), fluoroscopy settings sheet, electrosurgery grounding guide.</p>
<p>4. <strong>Post‑procedure Flowchart</strong> – maternal vitals → fetal monitoring → complication algorithm → discharge criteria.</p>
</div></details>
<details><summary><strong>14. Patient Education Handout (Key Points)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopy can be performed safely when medically indicated.  </li>
<li style="margin-left: 0px;">Risks are low but include preterm labor, radiation exposure (generally &lt;10 mGy).  </li>
<li style="margin-left: 0px;">You will be monitored before and after the procedure; fetal heart rate checks are routine.  </li>
<li style="margin-left: 0px;">Discuss any concerns with your GI and obstetric team; alternatives will be offered when possible.  </li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
